These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15553716)

  • 1. [A case of advanced non-small lung cancer responding to tumor suppressor p53 gene therapy].
    Kagawa S; Ohtani S; Tanaka N; Fujiwara T
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1788-90. PubMed ID: 15553716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P21 gene expression as an indicator for the activity of adenovirus-p53 gene therapy in non-small cell lung cancer patients.
    Boulay JL; Perruchoud AP; Reuter J; Bolliger C; Herrmann R; Rochlitz C
    Cancer Gene Ther; 2000 Sep; 7(9):1215-9. PubMed ID: 11023193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.
    Swisher SG; Roth JA; Komaki R; Gu J; Lee JJ; Hicks M; Ro JY; Hong WK; Merritt JA; Ahrar K; Atkinson NE; Correa AM; Dolormente M; Dreiling L; El-Naggar AK; Fossella F; Francisco R; Glisson B; Grammer S; Herbst R; Huaringa A; Kemp B; Khuri FR; Kurie JM; Liao Z; McDonnell TJ; Morice R; Morello F; Munden R; Papadimitrakopoulou V; Pisters KM; Putnam JB; Sarabia AJ; Shelton T; Stevens C; Shin DM; Smythe WR; Vaporciyan AA; Walsh GL; Yin M
    Clin Cancer Res; 2003 Jan; 9(1):93-101. PubMed ID: 12538456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer.
    Kandioler D; Stamatis G; Eberhardt W; Kappel S; Zöchbauer-Müller S; Kührer I; Mittlböck M; Zwrtek R; Aigner C; Bichler C; Tichy V; Hudec M; Bachleitner T; End A; Müller MR; Roth E; Klepetko W
    J Thorac Cardiovasc Surg; 2008 May; 135(5):1036-41. PubMed ID: 18455581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical study of adenoviral mediated p53 gene therapy for non-small cell lung cancer in Japan].
    Kagawa S; Fujiwara T; Tanaka N
    Gan To Kagaku Ryoho; 2003 Feb; 30(2):193-7. PubMed ID: 12610865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement.
    Roth JA; Swisher SG; Merritt JA; Lawrence DD; Kemp BL; Carrasco CH; El-Naggar AK; Fossella FV; Glisson BS; Hong WK; Khurl FR; Kurie JM; Nesbitt JC; Pisters K; Putnam JB; Schrump DS; Shin DM; Walsh GL
    Semin Oncol; 1998 Jun; 25(3 Suppl 8):33-7. PubMed ID: 9704675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival of patients with advanced non-small-cell lung cancer at Ubon Ratchathani Cancer Center, Thailand.
    Srisam-Ang K; Podhipak A; Narksawat K; Supaattagorn P; Tipayamongkholgul M
    Southeast Asian J Trop Med Public Health; 2005 Jul; 36(4):994-1006. PubMed ID: 16295558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.
    Hirai K; Koizumi K; Haraguchi S; Hirata T; Mikami I; Fukushima M; Yamagishi S; Kawashima T; Okada D; Shimizu K; Kawamoto M
    Ann Thorac Surg; 2005 Jan; 79(1):248-53. PubMed ID: 15620951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Locally advanced non-small cell lung cancer completely resected after induction therapy].
    Katsuragi N; Shiraishi Y; Kita H; Toishi M; Onda T; Tanaka S
    Kyobu Geka; 2008 Jan; 61(1):9-14. PubMed ID: 18186266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Gene therapy for lung cancer].
    Kataoka M; Fujiwara T; Tanaka N
    Nihon Geka Gakkai Zasshi; 2002 Feb; 103(2):244-9. PubMed ID: 11904988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 3' UTR IGF2R-A2/B2 variant is associated with increased tumor growth and advanced stages in non-small cell lung cancer.
    Kotsinas A; Evangelou K; Sideridou M; Kotzamanis G; Constantinides C; Zavras AI; Douglass CW; Papavassiliou AG; Gorgoulis VG
    Cancer Lett; 2008 Feb; 259(2):177-85. PubMed ID: 18037232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer.
    Fujiwara T; Tanaka N; Kanazawa S; Ohtani S; Saijo Y; Nukiwa T; Yoshimura K; Sato T; Eto Y; Chada S; Nakamura H; Kato H
    J Clin Oncol; 2006 Apr; 24(11):1689-99. PubMed ID: 16505415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment based on biological characteristics of lung cancer: biological differences between small cell and non-small cell lung cancer and gene therapy].
    Tanio Y
    Gan To Kagaku Ryoho; 1997 Oct; 24 Suppl 3():337-44. PubMed ID: 9369905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.
    Nemunaitis J; Dillman RO; Schwarzenberger PO; Senzer N; Cunningham C; Cutler J; Tong A; Kumar P; Pappen B; Hamilton C; DeVol E; Maples PB; Liu L; Chamberlin T; Shawler DL; Fakhrai H
    J Clin Oncol; 2006 Oct; 24(29):4721-30. PubMed ID: 16966690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicity and outcome of a phase II trial of taxane-based neoadjuvant chemotherapy and 3-dimensional, conformal, accelerated radiotherapy in locally advanced nonsmall cell lung cancer.
    Rojas AM; Lyn BE; Wilson EM; Williams FJ; Shah N; Dickson J; Saunders MI
    Cancer; 2006 Sep; 107(6):1321-30. PubMed ID: 16902985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A phase I trial of adenoviral p53 gene therapy for non-small cell lung cancer].
    Fujiwara T; Kataoka M; Kawamata O; Tanaka N
    Nihon Geka Gakkai Zasshi; 1999 Nov; 100(11):749-55. PubMed ID: 10629843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone.
    Huang EH; Liao Z; Cox JD; Guerrero TM; Chang JY; Jeter M; Borghero Y; Wei X; Fossella F; Herbst RS; Blumenschein GR; Moran C; Allen PK; Komaki R
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):779-85. PubMed ID: 17418967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of the p53 pathway and associated gene therapy in non-small cell lung cancers.
    Huang CL; Yokomise H; Miyatake A
    Future Oncol; 2007 Feb; 3(1):83-93. PubMed ID: 17280505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status of gene therapy for lung cancer and head and neck cancer.
    Moon C; Oh Y; Roth JA
    Clin Cancer Res; 2003 Nov; 9(14):5055-67. PubMed ID: 14613982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recombinant adenovirus-p53 gene therapy combined with radiotherapy for head and neck squamous-cell carcinoma].
    Zhang SW; Xiao SW; Liu CQ; Sun Y; Su X; Li DM; Xu G; Zhu GY; Xu B
    Zhonghua Zhong Liu Za Zhi; 2005 Jul; 27(7):426-8. PubMed ID: 16188130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.